Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
Rev Bras Hematol Hemoter ; 33(2): 131-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-23284261

RESUMO

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

4.
Rev. bras. hematol. hemoter ; 33(2): 131-139, 2011. ilus, tab
Artigo em Inglês | LILACS | ID: lil-596303

RESUMO

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.


Assuntos
Humanos , Resistência a Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Interferon-alfa/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva , Inibidores de Proteínas Quinases , Piperazinas/uso terapêutico , Trato Gastrointestinal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...